MedTrace Logo

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

NCT01458405 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2024-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.

Conditions

Interventions

BIOLOGICAL

CAP-1002 Allogeneic Cardiosphere-Derived Cells

Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells

DRUG

Placebo

Single, blinded, intracoronary infusion of a placebo solution

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • Capricor Inc.

    lead INDUSTRY

Principal Investigators

  • Frank Litvack, MD · Capricor Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-13
Primary Completion
2017-07-03
Completion
2019-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458405 on ClinicalTrials.gov